logo-loader
CSE:RVV OTCQB:RVVTF

Revive Therapeutics

Receive alerts
Market:
CSE
Market Cap:
$62.3 m
Price
0.38 CAD
Change
2.70%
52 weeks high
0.46
52 weeks low
0.03

In brief

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza strains including COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. 

Deep dive We explore the investor case for growth companies

Snapshot

The company is finalizing an FDA application to start Phase 3 clinical trial to evaluate Bucillamine in patients with lung inflammation